Myristoylated Protein Kinase C Peptide Inhibitor( 十四酰蛋白激酶C 抑制剂), Myr. RFARKGALRQKNV ( 分子量=1,754Da), 特异性地抑制钙依赖性蛋白激酶 C 和磷脂依赖性蛋白激酶 C (PKC)。其原理是基于PKC-α 和 PKC-β 的假底物结构域。该产品可直接用于激酶反应中。50μM 的十四酰蛋白激酶 C 可抑制的PKC 活性高于75%。
Myristoylated Protein Kinase C (PKC) Peptide Inhibitor, Myr. RFARKGALRQKNV (MW = 1,754 daltons), specifically inhibits calcium- and phospholipid-dependent protein kinase C (PKC). It is based on the pseudosubstrate region of PKC-α and PKC-β. It is supplied ready for use in kinase reactions. Greater than 75% inhibition of PKC activity is usually obtained with 50μM Myristoylated PKC Peptide Inhibitor.
Properties:
Concentration: 10mg/ml (peptide).
Molarity: 4.3mM.
Peptide Content: ≥ 70%. The mass of the peptide is verified by FAB/MS.
Molecular Weight: 1,754Da.
Features - Benefits
Cell Permeable: The Myristoylated Protein Kinase C Peptide Inhibitor is taken up by intact cells, which allows for in vivo PKC inhibition studies.
Applications
For more information, see the Protocols & Applications Guide.
References
Eichholtz, T. et al. (1993) J. Biol. Chem. 268, 1982–6.